| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Dipartimento di Medicina Clinica, Servizio di Fisiopatologia Respiratoria, Università "La Sapienza", 00185 Rome, Italy
Submitted 11 November 2003 ; accepted in final form 30 June 2004
 |
ABSTRACT |
|---|
 TOP ABSTRACT METHODSRESULTSDISCUSSIONREFERENCES |
|---|
E), carbon dioxide output, heart rate, inspiratory capacity (IC), Dys, and arterial partial pressure of CO2 were measured. Exercise endurance time increased significantly with heliox [9.0 (SD 4.5) vs. 4.2 (SD 2.0) min; P < 0.001]. This was associated with a significant reduction in lung DH at isotime (Iso), as reflected by the increase in IC [1.97 (SD 0.40) vs. 1.77 (SD 0.41) liters; P < 0.001] and a decrease in Dys [6 (SD 1) vs. 8 (SD 1) score; P < 0.001]. Heliox induced a state of relative hyperventilation, as reflected by the increase in E [38.3 (SD 7.7) vs. 35.5 (SD 8.8) l/min; P < 0.01] and E/carbon dioxide output [36.3 (SD 6.0) vs. 33.9 (SD 5.6); P < 0.01] at peak exercise and by the reduction in arterial partial pressure of CO2 at Iso [44 (SD 6) vs. 48 (SD 6) Torr; P < 0.05] and at peak exercise [46 (SD 6) vs. 48 (SD 6) Torr; P < 0.05]. The reduction in Dys at Iso correlated significantly (R = –0.75; P < 0.01) with the increase in IC induced by heliox. The increment induced by heliox in exercise endurance time correlated significantly with resting increment in resting forced expiratory in 1 s (R = 0.88; P < 0.01), increase in IC at Iso (R = 0.70; P < 0.02), and reduction in Dys at Iso (R = –0.71; P < 0.01). In chronic obstructive pulmonary disease, heliox breathing improves high-intensity exercise endurance capacity by increasing maximal ventilatory capacity and by reducing lung DH and Dys. chronic obstructive pulmonary disease; therapy
Breathing low-density gas mixture, such as heliox (79% He-21% O2), should improve lung mechanics and exercise capacity in ventilatory-limited COPD patients. Very few and not conclusive data, however, exist on the effect of heliox on exercise tolerance in COPD and, because of different exercise protocols used, no definitive conclusion can be drawn (8, 16, 24, 25). In ventilatory-limited COPD, because of its effects on turbulent flow resistance (10), heliox should improve exercise tolerance at a high level of ventilation, e.g., close to the patient's maximal ventilatory capacity. Surprisingly, no studies have evaluated the effects of heliox on DH, pulmonary gas exchange, or ultimately on exercise endurance capacity in COPD.
We tested the hypothesis that, by reducing the degree of lung DH and the severity of Dys, heliox should improve the ability of COPD patients to sustain high-intensity bouts of exercise. We were also interested to verify whether heliox, because of its convective properties, is capable of improving lung gas-exchange efficiency during exercise; we are not aware of studies addressing this issue in COPD.
In a group of patients with moderate to severe COPD, we measured the changes in lung mechanics and gas-exchange parameters induced by heliox breathing during exhaustive high-intensity exercise. Clinical implications may be derived, indicating new therapeutic strategy aimed at ameliorating exercise capacity in ventilatory-limited COPD patients, allowing them to sustain a high-power output for a period of time long enough to induce a significant training effect.
|
METHODS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
On the enrollment day, all of the patients performed spirometry, N2 wash-out (COSMED PFT, Rome, Italy), and arterial blood-gas analysis (IL 1640, Instrumentation Laboratory, Lexington, MA). On the same day, all subject underwent an incremental (5 W/min) cycle ergometer (Bosch, ERG 551) exercise to volitional fatigue to measure peak work rate (i.e., the largest work rate completed for 1 min) (Table 1).
On the experimental day (a minimum of 48 h after the incremental test), based on the results of the incremental test, the subjects performed two constant work rate (CWR) tests separated by 90-min intervals, while breathing room air or heliox (79% He-21% O2). The test sequence was randomized. Subjects were blinded with respect to the mixture being breathed, as was the investigator evaluating subjective responses and performing data analysis. Patients were allowed to adapt to the mouthpieces for 10 min, during which time they breathed the gas mixture, and resting data were acquired. Thereafter, a CWR exercise at 80% of the maximal work rate achieved on the enrollment day, with a pedaling frequency of 50 rpm, was performed until exhaustion. The same encouragement was given in all tests. The tests were interrupted when the patient, because of intolerable Dys and/or leg fatigue, was not able to keep the pedaling frequency of 50 rpm. At peak exercise, patients were asked to estimate the intensity of Dys and leg fatigue by using a 12-point visual scale (12). To verify data repeatability, 7 of 12 patients were reevaluated with an identical randomized protocol. Mean values of two tests for the same experimental condition were utilized for statistical purposes, after good repeatability in measured variables was confirmed. Spirometry and blood gases were repeated before each bout of exercise to confirm clinical stability.
Gas-exchange measurements.
Pulmonary gas exchange indexes were measured with the use of a breath-by-breath apparatus (COSMED Quark b2, Rome, Italy). Patients breathed through a mouthpiece attached to a photoelectric digital turbine (diameter 28 mm; resolution 4 ml) proximally linked to a two-way low-resistance valve (Hans Rudolph, 2700 large 2-way) that did not allow rebreathing. The inspiratory part of the valve was connected to a 30-liter Douglas bag in which the humidified mixtures (air/heliox), coming from gas tank mixtures, were collected. The same apparatus was utilized on air and on heliox. To attain an external apparatus resistance similar to that during air breathing, mesh screens were added to the tubing system during heliox breathing. Total resistance of the system was 0.6 cmH2O l/s at 3 l/s and 0.4 cmH2O l/s at 2 l/s during air breathing and 0.7 cmH2O l/s at 3 l/s and 0.4 cmH2O l/s at 2 l/s during heliox breathing. Expired gas was drawn from the distal part of the turbine by the use of a special sampler capillary of polymer Nafion (Permapure); CO2 concentration was determined by a rapid-response analyzer (CO2 infrared). Calibration of the system was performed, in air and heliox, immediately before each test, by using a 3-liter syringe to calibrate the turbine, and a two-point calibration of the gas analyzer using gas mixture from tanks of standard gases. Corrections for the transport delay, from the mouthpiece to the sensor, and for the rise time of the analyzers during the calibrations procedure, on air and on heliox, were taken into account (6). CO2 output (CO2; STPD) and minute ventilation (E; BTPS) were measured for each breath by the use of a computerized system. Arterial oxygen saturation was measured continuously at rest and during exercise by means of a pulse oximetry (BIOX 3740, Ohmeda, Liberty Corner, NY). Heart rate was derived from R-wave-to-R-wave intervals measured from a 12-lead ECG.
Blood samples.
Measurements of arterial partial pressure CO2 (PaCO2) were obtained on arterialized venous blood samples (17). A catheter was placed on a backhand vein and connected to a line, which allow sampling during the exercise. The blood was arterialized by means of an infrared lamp positioned 35 cm over the hand. The catheter was flushed with heparinized saline. To avoid spurious dilution, 2 ml of blood were discarded before collection of the blood sample. Each blood sample was drawn into a heparinized syringe and immediately analyzed (IL 1650, Instrumentation Laboratory). The physiological dead space-to-tidal volume ratio (VDs/VT), an index of lung gas exchange efficiency, was calculated by using the formula (28):
 |
Lung mechanics parameters.
FEV1 and IC were measured at rest, on air, and during heliox breathing, 10 min after the washin of the gas mixture. Resting maximal voluntary ventilation (MVV) was calculated by multiplying FEV1 x 35 (11). VT, respiratory frequency, inspiratory time, and expiratory time were measured continuously. Mean expiratory flow (MEF = VT/expiratory time) and duty cycle (inspiratory time/respiratory cycle duration) were calculated. The development of DH during exercise was evaluated by measuring IC every 2 min during exercise and immediately before the end; verbal encouragement was given to make a maximal effort on top of a maximal inspiration before relaxing. IC/E and the inspiratory reserve volume (IRV = IC – VT) were calculated.
Statistical analysis.
Group data are presented as means with SD. Differences among measured parameters were determined by paired t-test. Pearson's product-moment correlation coefficient (R) was used to detect correlation among criterion variables. The level of statistical significance was set at P < 0.05. Data repeatability was assessed by calculating the intraclass correlation coefficients (R2) (7) with the use of dedicated SPSS software.
|
RESULTS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
E and CO2 responses, on air and on heliox, for the entire group of patients studied are shown in Fig. 1. Endurance capacity increased significantly with heliox. At peak exercise, E was higher in heliox compared with air breathing, whereas at isotime (Iso; when the patients stopped exercising during air breathing) E was not different compared with air. CO2 was significantly lower during heliox at Iso exercise.
|
E, and with a reduction in heart rate, E/MVV, and DYS [6 (SD 1) vs. 8 (SD 1) score; P < 0.001]. At peak exercise, in heliox compared with air breathing, VT, IC, MEF, E, and E/CO2 were significantly higher. By contrast, arterial oxygen saturation and lung gas-exchange efficiency (i.e., VDs/VT) were not affected by heliox breathing during exercise.
|
|
|
End, where is change) induced by heliox correlated significantly with the increment in resting FEV1 (R = 0.88; P < 0.01), the increment of ICIso (ICIso) (R = 0.70, P < 0.02), and the reduction in Dys at Iso (DysIso) (Fig. 4; R = –0.71, P < 0.01). Moreover, the increment of ICIso (ICIso) correlated with the reduction in DysIso (Fig. 4; R = –0.75, P < 0.01). No other correlations between pertinent variables were found. In particular, the severity of resting airflow obstruction and/or patients' maximal exercise capacity did not correlate with ICISO and/or End.
|
|
|
DISCUSSION |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
E at peak exercise. Importantly, the improvement in maximal expiratory flow determined a significant reduction in DH and Dys, as reflected by the significant increase in IC, IRV, and IC/E and decrease in DysIso. All of these positive changes in lung mechanics allowed the patients to markedly improve exercise endurance time; the observed correlations between ICIso vs. DysIso, ICIso vs. End, and DysIso vs. End strongly support our hypothesis. Finally, it is likely that the exercise protocol used, capable of inducing high levels of ventilation relative to subject's maximal ventilation for a prolonged period of time, has amplified the effect of heliox breathing in reducing turbulent airway resistances. The beneficial effect of heliox on maximal E has been demonstrated in normal subjects (27) and in subjects with mild airflow obstruction (5). Some authors have stated that increase in maximal E induced by heliox occurs only in flow-limited subjects, and it is due to the reduction in respiratory impedance, which becomes greater as E becomes higher (5).
In COPD patients, Dys on exertion is multifactorial in origin. Previous studies have demonstrated a close relationship between Dys sensation and the level of ventilation achieved during exercise (13, 14, 26). However, the variability in Dys among COPD subjects for a given level of E suggests that other factors play an important role. In patients with chronic airflow limitation, in contrast to normal subjects, end-expiratory lung volume (EELV) increases during exercise, and, to ensure an adequate increase in VT and E, COPD patients should use their IRV and develop DH. O'Donnell and Webb (23) were among the first to describe a close relationship between the degree of DH and the degree of Dys sensation in COPD patients during exercise. In their original study, they observed that the change in EELV was the strongest predictor of exertional breathlessness, accounting for 38% of variance in Borg scores (23). The results of the present study, according to which heliox breathing lowers the degree of Dys by reducing the degree of DH, are in agreement with the observation reported by O'Donnell and Webb (23).
In normal subjects during incremental exercise, Babb (3) observed that heliox reduces EELV (without a significant increment in end-inspiratory lung volume) and increases maximal E. The same author, in a group of patients with mild airflow limitation, showed an increase in maximal expiratory flow as for the effect of heliox (4, 5). Our results are in agreement with those of Babb: with heliox, we observed an increase in maximal E and a reduction in DH. The reduction in DH was observed in all but one patient studied: the improvement in endurance time was more pronounced in those patients who showed a greater reduction in DH; in three patients heliox induced an increase in ICIso of >250 ml that was associated with a remarkable improvement in endurance time.
In the present study, we observed a significant reduction in Dys associated with a small but significant increase in IC. Our results are in keeping with previous work in this field. O'Donnell and coworkers (21) observed a correlation between the reduction in Dys sensation and the increase in IC induced by 60% oxygen breathing. Very recently, Man and coworkers (15), who studied the effects of salmeterol on exercise DH, reported a significant reduction in Dys sensation associated with very small increments of IC. Again, we believe that the high-intensity CWR test utilized allowed us to clearly detect the beneficial effect of small changes in lung mechanics induced by heliox breathing on exercise capacity. In this respect, the observed small increment in FEV1 (+0.16 liter) induced by heliox at rest can be roughly translated in an increase in maximal E of +5.6 l/min that, in a COPD patient with 1.3 liter of FEV1, predicts a +12% increase in maximal ventilatory capacity. Such a difference may significantly influence submaximal exercise capacity in moderate to severe COPD patients, as suggested by Neder and coworkers (19) in their original study on the exercise power-duration relationship in COPD.
Our results are in apparent contrast with those of Raimondi and coworkers (24) that utilized an experimental setting similar to ours but reached different conclusions. Possible explanations for the differences observed are as follows: 1) the more severe patients studied by Raimondi et al. (mean FEV1 0.74 liter) compared with ours (mean FEV1 1.14 liter); and 2) more importantly, the different exercise protocol used to select the work rate for the CWR exercise. Raimondi et al. used a maximal test with 18 W/min increments that lasted only 4–6 min, whereas we used a 5 W/min protocol that allowed us to better select the workload for the constant work test. In the study of Raimondi, in fact, the CWR test elicited a supramaximal response in E that was 127% of the predicted MVV; by contrast, in our study, E during CWR exercise on air was 89% of predicted MVV.
In normal individuals, heliox breathing during exercise induces sustained hyperventilation and hypocapnia (3, 9, 27). The effect on E is more evident during high-intensity efforts (3, 4), because the increment in E is mostly due to an increase in VT (27). Various mechanisms have been suggested to explain the state of hyperventilation induced by heliox. Ward and coworkers (27) proposed that the sustained low-PaCO2 values observed in normal subjects are due, at least in part, to a fall in airway resistances at a high ventilatory rate. In agreement with the previous above-mentioned published data, we observed higher VT, MEF, E/CO2, and lower PaCO2 values at peak exercise, suggesting that, even in severely ventilatory-limited COPD patients, heliox breathing induces a state of "relative hyperventilation" (e.g., relative to the level of CO2 produced). Regarding the hypothesis that heliox, because of its convective properties, may also improve exercise lung gas-exchange efficiency in COPD, we did not find any significant change in VDs/VT at rest or during exercise. Nemery and coworkers (20) reported that heliox breathing does not affect VDs/VT at rest and during moderate CWR exercise in normal individuals. To our knowledge, no data are available in the literature on the effect of heliox on arterial blood gases and on VDs/VT in COPD with which to compare our data. The results of the present study do not support a beneficial effect of heliox on lung gas mixing and exchange in COPD during exercise.
Interestingly, the changes in lung mechanics induced by heliox were associated with a reduction in CO2 values at Iso. Whether these changes may reflect a reduction in metabolic demand from respiratory and/or peripheral exercise muscles, we cannot answer.
In conclusion, heliox breathing, by reducing airflow limitation, DH, and Dys sensation, is capable of improving high-intensity exercise endurance capacity in moderate to severe COPD patients. We are aware of some potential limitations of our study, particularly in terms of the generalizability of the results to all COPD populations. Our results, however, suggest that heliox may be helpful, particularly in patients with severe airflow limitation and high levels of exercise DH. Further studied are needed to verify the potential role of heliox supplementation during exercise rehabilitation programs in COPD patients.
|
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
|
REFERENCES |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  B. J. Whipp and S. A. Ward Quantifying intervention-related improvements in exercise tolerance Eur. Respir. J., June 1, 2009; 33(6): 1254 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Chiappa, F. Queiroga Jr., E. Meda, L. F. Ferreira, F. Diefenthaeler, M. Nunes, M. A. Vaz, M. C. L. Machado, L. E. Nery, and J. A. Neder Heliox Improves Oxygen Delivery and Utilization during Dynamic Exercise in Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., June 1, 2009; 179(11): 1004 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Murgu and H. G. Colt Tracheobronchoplasty for Severe Tracheobronchomalacia Chest, May 1, 2009; 135(5): 1403 - 1404. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Butcher, O. Lagerquist, D. D. Marciniuk, S. R. Petersen, D. F. Collins, and R. L. Jones Relationship between ventilatory constraint and muscle fatigue during exercise in COPD Eur. Respir. J., April 1, 2009; 33(4): 763 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Eves, L. C. Sandmeyer, E. Y. Wong, L. W. Jones, G. F. MacDonald, G. T. Ford, S. R. Petersen, M. D. Bibeau, and R. L. Jones Helium-Hyperoxia: A Novel Intervention To Improve the Benefits of Pulmonary Rehabilitation for Patients With COPD Chest, March 1, 2009; 135(3): 609 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. West, P. D. Wagner, J. A. Neder, G. L. Scano, N. L. Jones, S. G. Zakynthinos, I. Vogiatzis, L. Nici, P. M. Calverley, H. R. Gosker, et al. The major limitation to exercise performance in COPD is inadequate energy supply to the respiratory and locomotor muscles vs. lower limb muscle dysfunction vs. dynamic hyperinflation J Appl Physiol, August 1, 2008; 105(2): 758 - 762. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Clini and N. Ambrosino Nonpharmacological treatment and relief of symptoms in COPD Eur. Respir. J., July 1, 2008; 32(1): 218 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Marciniuk, S. J. Butcher, J. K. Reid, G. F. MacDonald, N. D. Eves, R. Clemens, and R. L. Jones The Effects of Helium-Hyperoxia on 6-min Walking Distance in COPD: A Randomized, Controlled Trial Chest, June 1, 2007; 131(6): 1659 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. O'Donnell, R. B. Banzett, V. Carrieri-Kohlman, R. Casaburi, P. W. Davenport, S. C. Gandevia, A. F. Gelb, D. A. Mahler, and K. A. Webb Pathophysiology of Dyspnea in Chronic Obstructive Pulmonary Disease: A Roundtable Proceedings of the ATS, May 1, 2007; 4(2): 145 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Palange, S. A. Ward, K-H. Carlsen, R. Casaburi, C. G. Gallagher, R. Gosselink, D. E. O'Donnell, L. Puente-Maestu, A. M. Schols, S. Singh, et al. Recommendations on the use of exercise testing in clinical practice Eur. Respir. J., January 1, 2007; 29(1): 185 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. A. Calverley Exercise and dyspnoea in COPD Eur. Respir. Rev., December 1, 2006; 15(100): 72 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. M. Wouters Nonpharmacological modulation of dynamic hyperinflation Eur. Respir. Rev., December 1, 2006; 15(100): 90 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Eves, S. R. Petersen, M. J. Haykowsky, E. Y. Wong, and R. L. Jones Helium-Hyperoxia, Exercise, and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 763 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Casaburi Combination therapy for exercise intolerance in COPD. Thorax, July 1, 2006; 61(7): 551 - 552. [Full Text] [PDF]
|
|
|
|
|
|
P. M. A. Calverley Dynamic Hyperinflation: Is It Worth Measuring? Proceedings of the ATS, May 1, 2006; 3(3): 239 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Laude, N. C. Duffy, C. Baveystock, B. Dougill, M. J. Campbell, R. Lawson, P. W. Jones, and P. M. Calverley The Effect of Helium and Oxygen on Exercise Performance in Chronic Obstructive Pulmonary Disease: A Randomized Crossover Trial Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 865 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Casaburi and J. Porszasz Reduction of hyperinflation by pharmacologic and other interventions. Proceedings of the ATS, January 1, 2006; 3(2): 185 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Fessler Collateral Ventilation, the Bane of Bronchoscopic Volume Reduction Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 423 - 424. [Full Text] [PDF]
|
|
|
|
|
|
P. M. A. Calverley and N. G. Koulouris Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology Eur. Respir. J., January 1, 2005; 25(1): 186 - 199. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
) and on heliox (
) in chronic obstructive pulmonary disease (COPD) patients (n = 12). Mean endurance time increased significantly with heliox. Mean 
